Compare CTSO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTSO | IXHL |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 97.6M |
| IPO Year | 2008 | 2024 |
| Metric | CTSO | IXHL |
|---|---|---|
| Price | $0.73 | $5.95 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | 67.1K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $22,503,908.00 | $12,000.00 |
| Revenue This Year | $7.29 | N/A |
| Revenue Next Year | $8.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.60 | $0.11 |
| 52 Week High | $1.39 | $5.45 |
| Indicator | CTSO | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 90.18 |
| Support Level | $0.62 | $0.31 |
| Resistance Level | $0.84 | N/A |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | 0.01 | 0.40 |
| Stochastic Oscillator | 59.46 | 91.05 |
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.